Stock IRLAB A IRLAB THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

All News IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Delayed Nasdaq Stockholm
Other stock markets
 12:07:53 17/05/2024 BST 		5-day change 1st Jan Change
15.1 SEK +2.37% Intraday chart for IRLAB Therapeutics AB +15.71% +101.33%
05-08 Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024
05-07 IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024
IRLAB publishes interim report for the period January-March 2024
AQ
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy
CI
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy
AQ
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
CI
IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757
AQ
IRLAB: Invitation to the interim report for Q1 2024 presentation and webcast
AQ
IRLAB publishes Annual Report for 2023
AQ
IRLAB to present at Redeye Investor Forum
AQ
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam
AQ
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam
CI
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam
AQ
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis
CI
IRLAB Therapeutics : mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis
PU
IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis
AQ
IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG
AQ
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7
AQ
IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases
AQ
IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam
AQ
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IRLAB A Stock
  4. News IRLAB Therapeutics AB